PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30709876-0	2019	Refractory and metastatic infantile fibrosarcoma harboring LMNA-NTRK1 fusion shows complete and durable response to crizotinib.	Crizotinib	116-126	lamin A/C	Homo sapiens	59-63	
30709876-4	2019	In this report, we outline the use of integrative clinical sequencing (ICS) including RNA-seq in a patient with refractory, metastatic IFS to reveal an unusual fusion (LMNA-NTRK1), not detected by routine FISH testing, which was treated with oral crizotinib and resulted in a complete and durable long-term response.	Crizotinib	247-257	lamin A/C	Homo sapiens	168-172	
30134855-0	2018	A primary undifferentiated pleomorphic sarcoma of the lumbosacral region harboring a LMNA-NTRK1 gene fusion with durable clinical response to crizotinib: a case report.	Crizotinib	142-152	lamin A/C	Homo sapiens	85-89	
30134855-7	2018	The patient then began treatment with crizotinib at an oral dose of 450 mg per day, based on the detection of a LMNA-NTRK1 fusion gene in the tumor by next-generation sequencing.	Crizotinib	38-48	lamin A/C	Homo sapiens	112-116	
30134855-9	2018	CONCLUSIONS: The LMNA-NTRK1 fusion was likely the molecular driver of tumorigenesis and metastasis in this patient, and the observed effectiveness of crizotinib treatment provides clinical validation of this molecular target.	Crizotinib	150-160	lamin A/C	Homo sapiens	17-21	
26563356-0	2016	Evaluation of a Congenital Infantile Fibrosarcoma by Comprehensive Genomic Profiling Reveals an LMNA-NTRK1 Gene Fusion Responsive to Crizotinib.	Crizotinib	133-143	lamin A/C	Homo sapiens	96-100